| Literature DB >> 32341700 |
Volodymyr Goshchynsky1, Bogdan Migenko1, Oleg Lugoviy1, Ludmila Migenko2.
Abstract
The problem of lower limb preservation with symptoms of critical ischemia, resulting in necrosis of the distal foot portion, remains open. These cases require solving few tactical questions, such as the primary revascularization method, limb-preserving amputation, stimulation of regeneration, and finally, determining the criteria for auto-dermal transplantation. We analyzed 29 patient cases with critical lower limb ischemia of fourth grade, according to the Fontaine classification (or the sixth category according to Rutherford's classification), who underwent partial foot amputation due to dry gangrene and were threated using PRGF®-ENDORET® platelet-rich plasma and platelet-rich fibrin technology. The control group was comprised of 21 patients who received traditional postoperative wound treatment. All patients went through a combination of transluminal revascularization and platelet-rich plasma to create a "therapeutic" neoangiogenic effect. Indications for these procedures were severe distal arterial occlusion and stenosis. Using transluminal procedures with platelet-rich plasma therapy improves the blood perfusion to the distal portions of the limb in patients with critical ischemia in a short time, which is an informative diagnostic criterion for wound healing after amputation. Plasmatic membranes create an optimal environment for tissue regeneration, thus reducing the wound closure time using an auto-dermal transplant. ©Carol Davila University Press.Entities:
Keywords: PRF-platelet-rich fibrin; PRGF-platelet-rich growth factor; PRP- platelet-rich plasma; foot amputation; limb revascularization; wound healing
Mesh:
Substances:
Year: 2020 PMID: 32341700 PMCID: PMC7175431 DOI: 10.25122/jml-2020-0028
Source DB: PubMed Journal: J Med Life ISSN: 1844-122X
Figure 1:Perivascular VEGF plasma injection (PRGF®-ENDORET®)
Figure 2:Wound closure using a plasmatic membrane.
Skin temperature on angiosomic areas after revascularization.
| Measuring areas | Preoperative | 7th day after surgery | 14th day after surgery |
|---|---|---|---|
| 33.4 ± 0.65 | 36.1 ± 0.26* | 35.9 ± 0.33* | |
| 33.7 ± 0.49 | 35.9 ± 0.38* | 38 35.3 ± 0.57* | |
| 33.8 ± 0.56 | 36.0 ± 0.39* | 35.8 ± 0.46* | |
| 33.6 ± 0.86 | 35.9 ± 0.32* | 35.4 ± 0.81* | |
| 33.7 ± 0.32 | 35.9 ± 0.44* | 35.6 ± 0.41* | |
| 33.5 ± 0.38 | 35.1 ± 0.34* | 35.1 ± 0.42* | |
| 33.3 ± 0.52 | 35.1 ± 0.17* | 34.7 ± 0.44* | |
| 33.2 ± 0.76 | 34.9 ± 0.12* | 34.5 ± 0.56* |
Note: * р<0.05comparing to preoperative results.
Transcutaneous oximetry for surgery after the 7th and 14th day after transluminal surgery and PRP-therapy.
| tcpO2 | N=50 | ||
|---|---|---|---|
| Pre surgery | 7th day after surgery | 14th day after surgery | |
| I degree - (tcpO2 > 30 mmHg) | - | 6 | 18 |
| II degree - (tcpO2 20-30 mmHg) | 12 | 29 | 32 |
| III degree - (tcpO2 < 20 mmHg) | 38 | 15 | - |
Starting cytokine levels (pg/ml) in patients’ plasma.
| Group | IL - 1β | IL- 4 | TNF – α | IF– γ |
|---|---|---|---|---|
| Control | 807.72 ± 20.59 | 8.54 ± 0.73 | 23.46 ± 2.29 | 45.27 ± 4.15 |
| 1st | 526.60 ± 18.95** | 3.77 ± 0.19*** | 96.87 ± 5.06*** | 10.41 ± 0.89*** |
| 2nd | 554.32 ± 39.81* | 3.56 ± 0.42*** | 118.80 ± 8.93*** | 9.76 ± 1.01*** |
Note: * – p<0.05. ** – p<0.01. *** – p<0.001 comparing to the control group.